Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 42 clinical trials
Identification of Predictive Biomarkers for Response to Biologic Therapies in Inflammatory Bowel Disease

Prospective, multicentre trial which the biologic treatment will be initiated by clinical indication. The treatment selection anti-TNF (infliximab, adalimumab or golimumab), vedolizumab and

vedolizumab
infliximab
tumor necrosis factor alpha
inflammatory bowel disease
golimumab
  • 32 views
  • 03 Sep, 2021
  • 19 locations
Value of Pharmacokinetic Assays in the Prediction of Therapeutic Response in Ulcerative Colitis (PREDIRESPUC)

Vedolizumab (VDZ) is a monoclonal antibody that binds to the heterodimer 47 integrin and which has shown its efficacy in Ulcerative Colitis (UC) by inducing and maintaining clinical response

vedolizumab
crohn's disease
budesonide
mesalamine
prednisone
  • 0 views
  • 09 Feb, 2022
  • 3 locations
Autologous Stem Cell Transplant for Crohn's Disease

Investigators' plan in this study is to incorporate the drug Vedolizumab after transplant to test if this drug will improve remission and make patients healthier. Patients may qualify to take part in

vedolizumab
cyclophosphamide
methotrexate
tumor necrosis factor alpha
inflammatory bowel disease
  • 66 views
  • 25 Jan, 2021
  • 1 location
Pharmacologic Weight Loss as Adjunct Therapy for Ulcerative Colitis in Obese Patients

starting on a new biologic agent (infliximab, adalimumab, golimumab, vedolizumab). The overall objective is to (1) evaluate the efficacy, safety and tolerability of phentermine-topiramate, and (2

  • 0 views
  • 05 Feb, 2021
  • 1 location
Impact of Fecal Microbiota Transplantation in Ulcerative Colitis

Ulcerative colitis (UC) is a chronic relapsing inflammatory bowel disease. UC pathogenesis remains poorly understood but involves an inappropriate immune response toward an unbalanced gut microbiota (called dysbiosis) in predisposed hosts. The purpose of this study is to determine the effect of the fecal microbiota transplantation on UC.

Accepts healthy volunteers
microbiota
inflammatory bowel disease
dysbiosis
body mass index
  • 0 views
  • 03 Nov, 2021
  • 1 location
A Comparative Study of MRI, US and CE for Assessing Treatment Response in Known Crohn's Disease

The aim of this study is to evaluate non-invasive imaging techniques for assessing treatment response in known Crohn's disease. Comparing imaging modalities: The applicability of small bowel colon capsule endoscopy (SBCCE), magnetic resonance enterocolonography (MREC) and ultrasound (US) for diagnosing ulcer healing after medical treatment in patients with symptomatic Crohn's …

crohn's disease
corticosteroids
capsule endoscopy
ulceration
endoscopy
  • 5 views
  • 26 Feb, 2022
  • 1 location
The CURE - CD Trial

A prospective randomized three-arms controlled trial of Crohn's Disease (CD) patients in remission of <24 months duration. Patients will undergo screening by Magnetic Resonance Enterography (MRE) and patency capsule, and (if agreeing by separate consent) a baseline colonoscopy. Patients in whom patency of small bowel is proven will undergo video-capsule …

enteropathy
capsule endoscopy
endoscopy
remission
  • 7 views
  • 05 Mar, 2022
  • 1 location
An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab

Background Crohn s disease (CD) is an inflammatory bowel disease. It causes inflammation of the gut. Symptoms may include diarrhea, abdominal pain, fatigue, weight loss and malnutrition. CD has no cure, but symptoms can sometimes be controlled with medicine. Researchers want to see if it is safe to treat CD …

ciprofloxacin
vedolizumab
budesonide
maintenance treatment
tumor necrosis factor alpha
  • 53 views
  • 15 Jun, 2022
  • 1 location
Is the Endoscopic Remission Evaluation, Using the CREDO 1 Index / Score in CD Patients in Clinical Remission at Baseline, Predictive of Sustained Clinical Remission Using a 2-year Follow up (CREDO2)

The CREDO 2 study follows CREDO 1 study, which aims to construct an objective evaluation of endoscopic remission in Crohn's Disease (CD). In addition to reproducibility and validation, the predictive value of this remission evaluation needs to be tested in different settings to valorise its usefulness in clinical practice and …

vedolizumab
remission
endoscopy
fecal calprotectin
  • 45 views
  • 02 Mar, 2022
  • 11 locations
COLISURG : Exploratory Analysis of Sexual Function and the Impact of Biotherapies on Postoperative Morbidity.

other biotherapies including vedolizumab. All studies are retrospective series with small sample size. Here again the conclusion remain contradictory. Lightner et al. showed an increased risk of

vedolizumab
anal anastomosis
ileal reservoirs
tumor necrosis factor
  • 0 views
  • 05 Aug, 2021
  • 20 locations